- Home
- ALKT vs VRDN Comparison
ALKT vs VRDN Comparison
Compare ALKT & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKT
- VRDN
- Stock Information
- Founded
- ALKT 2007
- VRDN 2006
- Country
- ALKT United States
- VRDN United States
- Employees
- ALKT N/A
- VRDN N/A
- Industry
- ALKT EDP Services
- VRDN Medical Specialities
- Sector
- ALKT Technology
- VRDN Health Care
- Exchange
- ALKT Nasdaq
- VRDN Nasdaq
- Market Cap
- ALKT 2.6B
- VRDN 2.7B
- IPO Year
- ALKT 2021
- VRDN N/A
- Fundamental
- Price
- ALKT $21.31
- VRDN $31.77
- Analyst Decision
- ALKT Buy
- VRDN Strong Buy
- Analyst Count
- ALKT 8
- VRDN 11
- Target Price
- ALKT $35.88
- VRDN $39.00
- AVG Volume (30 Days)
- ALKT 1.9M
- VRDN 1.9M
- Earning Date
- ALKT 10-30-2025
- VRDN 11-05-2025
- Dividend Yield
- ALKT N/A
- VRDN N/A
- EPS Growth
- ALKT N/A
- VRDN N/A
- EPS
- ALKT N/A
- VRDN N/A
- Revenue
- ALKT $412,504,000.00
- VRDN $70,789,000.00
- Revenue This Year
- ALKT $35.49
- VRDN N/A
- Revenue Next Year
- ALKT $23.99
- VRDN $37,670.06
- P/E Ratio
- ALKT N/A
- VRDN N/A
- Revenue Growth
- ALKT 30.72
- VRDN 23340.07
- 52 Week Low
- ALKT $18.71
- VRDN $9.90
- 52 Week High
- ALKT $41.77
- VRDN $32.54
- Technical
- Relative Strength Index (RSI)
- ALKT 49.26
- VRDN 76.72
- Support Level
- ALKT $20.76
- VRDN $28.33
- Resistance Level
- ALKT $21.86
- VRDN $32.54
- Average True Range (ATR)
- ALKT 0.85
- VRDN 1.11
- MACD
- ALKT 0.28
- VRDN 0.24
- Stochastic Oscillator
- ALKT 81.36
- VRDN 87.23
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company's solution, the Alkami Digital Banking Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency, all with the support of a proprietary, true cloud-based, multi-tenant architecture.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).